Tag: Nerandomilast

Unfortunately, no drug has been proven to reverse established lung fibrosis completely. Current FDA-approved medications focus on slowing disease progression, but a wave of emerging therapies is now investigating ways to halt or even repair lung scarring in the ongoing search for what drugs reverse lung fibrosis.

Fibrotic diseases, characterized by organ scarring, represent a significant health burden, with idiopathic pulmonary fibrosis (IPF) being a primary example [1.2.2]. As of 2025, the key question, 'What is the new anti-fibrotic drug?', points towards nerandomilast, a promising agent nearing potential FDA approval [1.2.1, 1.2.5].